DARZALEX, generically known as daratumumab, is a monoclonal antibody used primarily in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It works by targeting and binding to a specific protein found on the surface of cancer cells, called CD38, which plays a significant role in the growth and survival of myeloma cells. By attaching to these cells, DARZALEX helps the immune system to detect and destroy them. It is often used in combination with other medications to enhance its effectiveness. Administered through intravenous infusion, DARZALEX has become a key component in the management of multiple myeloma, offering hope to patients with this challenging condition.